Lentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133/p85/p-AKT signaling axis
Yan Liu, Lufei Yang, Junxi Liu, Zihao He, Jingyi Wang, Yu Zhang, Kaiping Wang, Jinglin Wang · 2025
Read Lentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133/p85/p-AKT signaling axis by Yan Liu, Lufei Yang, Junxi Liu, Zihao He, Jingyi Wang, Yu Zhang, Kaiping Wang, Jinglin Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12727974.txt.
Description
Yan Liu and co-authors published a study in 2025 on a mushroom compound and colon cancer. Colon cancer often comes back and resists drugs, in part due to stem-like cancer cells. Such cells can regrow a tumor after treatment. The compound, drawn from a fungus, is known to boost the immune system.
The team tested the compound on two colon cancer cell lines in the lab. It slowed cell growth and cut the stem-like traits of the cells. Tests showed the compound binds a surface protein found on these stem-like cells. By binding there, it shuts down a growth signal chain inside the cell. The authors say plant and fungus sugars like this one merit more study as cancer drugs.
Catalog record
| CREATOR | Yan Liu, Lufei Yang, Junxi Liu, Zihao He, Jingyi Wang, Yu Zhang, Kaiping Wang, Jinglin Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |